Listed

Corvus Pharmaceuticals, Inc.

CRVSNasdaqCIK 1626971HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$19.3m, Q2 FY2026
Net income−$18.0m, Q2 FY2026
Corvus Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m4.0Research and development, Q3 FY2023, three months to 2023-09-30$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure4.0Research and development, Q4 FY2023, three months to 2023-12-31$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure4.1Research and development, Q1 FY2024, three months to 2024-03-31$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure4.1Research and development, Q2 FY2024, three months to 2024-06-30$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure5.2Research and development, Q3 FY2024, three months to 2024-09-30$5.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure6.0Research and development, Q4 FY2024, three months to 2024-12-31$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure7.5Research and development, Q1 FY2025, three months to 2025-03-31$7.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure7.9Research and development, Q2 FY2025, three months to 2025-06-30$7.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure8.5Research and development, Q3 FY2025, three months to 2025-09-30$8.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure9.9Research and development, Q4 FY2025, three months to 2025-12-31$9.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure11.2Research and development, Q1 FY2026, three months to 2026-03-31$11.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure16.0Research and development, Q2 FY2026, three months to 2026-06-30$16.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Operating income$m(5.6)Operating income, Q3 FY2023, three months to 2023-09-30−$5.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure(5.7)Operating income, Q4 FY2023, three months to 2023-12-31−$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(6.3)Operating income, Q1 FY2024, three months to 2024-03-31−$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure(5.9)Operating income, Q2 FY2024, three months to 2024-06-30−$5.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure(7.3)Operating income, Q3 FY2024, three months to 2024-09-30−$7.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure(8.1)Operating income, Q4 FY2024, three months to 2024-12-31−$8.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(9.9)Operating income, Q1 FY2025, three months to 2025-03-31−$9.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(10.3)Operating income, Q2 FY2025, three months to 2025-06-30−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure(10.6)Operating income, Q3 FY2025, three months to 2025-09-30−$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure(12.2)Operating income, Q4 FY2025, three months to 2025-12-31−$12.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(14.9)Operating income, Q1 FY2026, three months to 2026-03-31−$14.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(19.3)Operating income, Q2 FY2026, three months to 2026-06-30−$19.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001558370-24-015306. Derived: 9-month figure less the 6-month figure.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-06, accession 0001558370-24-011076. Derived: 6-month figure less the 3-month figure.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001558370-24-015306. Derived: 9-month figure less the 6-month figure.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001104659-26-091975. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reported0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001104659-26-091975. Derived: 6-month figure less the 3-month figure.Report this figure
Net income$m(6.0)Net income, Q3 FY2023, three months to 2023-09-30−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure(6.7)Net income, Q4 FY2023, three months to 2023-12-31−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(5.7)Net income, Q1 FY2024, three months to 2024-03-31−$5.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure(4.3)Net income, Q2 FY2024, three months to 2024-06-30−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure(40.2)Net income, Q3 FY2024, three months to 2024-09-30−$40.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure(12.1)Net income, Q4 FY2024, three months to 2024-12-31−$12.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure15.2Net income, Q1 FY2025, three months to 2025-03-31$15.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure(8.0)Net income, Q2 FY2025, three months to 2025-06-30−$8.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure(10.2)Net income, Q3 FY2025, three months to 2025-09-30−$10.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure(12.3)Net income, Q4 FY2025, three months to 2025-12-31−$12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(13.7)Net income, Q1 FY2026, three months to 2026-03-31−$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure(18.0)Net income, Q2 FY2026, three months to 2026-06-30−$18.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Diluted EPS$ per share(0.12)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figurenot reported(0.12)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure(0.07)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure(0.60)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figurenot reported(0.13)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(0.10)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure(0.12)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figurenot reported(0.15)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(0.19)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Basic EPS$ per share(0.12)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figurenot reported(0.12)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure(0.07)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure(0.60)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figurenot reported0.21Basic EPS, Q1 FY2025, three months to 2025-03-31$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(0.10)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure(0.12)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figurenot reported(0.15)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(0.19)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure

Balance sheet

Cash and equivalents$18.9m, Q2 FY2026
Shareholders' equity$225.3m, Q2 FY2026
Corvus Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m20.1Cash and equivalents, Q3 FY2023, at 2023-09-30$20.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0001558370-23-017981.Report this figure12.6Cash and equivalents, FY2023, at 2023-12-31$12.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-25, accession 0001558370-25-003621.Report this figure7.5Cash and equivalents, Q1 FY2024, at 2024-03-31$7.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure14.8Cash and equivalents, Q2 FY2024, at 2024-06-30$14.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0001558370-24-011076.Report this figure4.7Cash and equivalents, Q3 FY2024, at 2024-09-30$4.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure8.7Cash and equivalents, FY2024, at 2024-12-31$8.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001104659-26-027047.Report this figure5.0Cash and equivalents, Q1 FY2025, at 2025-03-31$5.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure14.7Cash and equivalents, Q2 FY2025, at 2025-06-30$14.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure2.9Cash and equivalents, Q3 FY2025, at 2025-09-30$2.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure4.6Cash and equivalents, FY2025, at 2025-12-31$4.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure40.1Cash and equivalents, Q1 FY2026, at 2026-03-31$40.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure18.9Cash and equivalents, Q2 FY2026, at 2026-06-30$18.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Current assets$m33.1Current assets, Q3 FY2023, at 2023-09-30$33.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0001558370-23-017981.Report this figure28.0Current assets, FY2023, at 2023-12-31$28.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-25, accession 0001558370-25-003621.Report this figure22.9Current assets, Q1 FY2024, at 2024-03-31$22.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure48.3Current assets, Q2 FY2024, at 2024-06-30$48.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001558370-24-011076.Report this figure42.9Current assets, Q3 FY2024, at 2024-09-30$42.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure54.4Current assets, FY2024, at 2024-12-31$54.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001104659-26-027047.Report this figure45.5Current assets, Q1 FY2025, at 2025-03-31$45.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure75.8Current assets, Q2 FY2025, at 2025-06-30$75.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure66.9Current assets, Q3 FY2025, at 2025-09-30$66.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure58.2Current assets, FY2025, at 2025-12-31$58.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure240Current assets, Q1 FY2026, at 2026-03-31$239.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure221Current assets, Q2 FY2026, at 2026-06-30$221.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Total assets$m51.9Total assets, Q3 FY2023, at 2023-09-30$51.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0001558370-23-017981.Report this figure45.6Total assets, FY2023, at 2023-12-31$45.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-25, accession 0001558370-25-003621.Report this figure40.1Total assets, Q1 FY2024, at 2024-03-31$40.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure64.6Total assets, Q2 FY2024, at 2024-06-30$64.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001558370-24-011076.Report this figure58.8Total assets, Q3 FY2024, at 2024-09-30$58.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure68.9Total assets, FY2024, at 2024-12-31$68.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001104659-26-027047.Report this figure59.4Total assets, Q1 FY2025, at 2025-03-31$59.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure89.5Total assets, Q2 FY2025, at 2025-06-30$89.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure80.5Total assets, Q3 FY2025, at 2025-09-30$80.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure71.1Total assets, FY2025, at 2025-12-31$71.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure253Total assets, Q1 FY2026, at 2026-03-31$253.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure239Total assets, Q2 FY2026, at 2026-06-30$239.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Current liabilities$m7.3Current liabilities, Q3 FY2023, at 2023-09-30$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0001558370-23-017981.Report this figure6.9Current liabilities, FY2023, at 2023-12-31$6.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-25, accession 0001558370-25-003621.Report this figure6.7Current liabilities, Q1 FY2024, at 2024-03-31$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure13.3Current liabilities, Q2 FY2024, at 2024-06-30$13.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001558370-24-011076.Report this figure46.4Current liabilities, Q3 FY2024, at 2024-09-30$46.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure35.4Current liabilities, FY2024, at 2024-12-31$35.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001104659-26-027047.Report this figure9.3Current liabilities, Q1 FY2025, at 2025-03-31$9.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure8.5Current liabilities, Q2 FY2025, at 2025-06-30$8.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure8.1Current liabilities, Q3 FY2025, at 2025-09-30$8.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure9.4Current liabilities, FY2025, at 2025-12-31$9.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure12.1Current liabilities, Q1 FY2026, at 2026-03-31$12.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure13.7Current liabilities, Q2 FY2026, at 2026-06-30$13.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Total liabilities$m7.7Total liabilities, Q3 FY2023, at 2023-09-30$7.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0001558370-23-017981.Report this figure6.9Total liabilities, FY2023, at 2023-12-31$6.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-25, accession 0001558370-25-003621.Report this figure6.7Total liabilities, Q1 FY2024, at 2024-03-31$6.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure13.3Total liabilities, Q2 FY2024, at 2024-06-30$13.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001558370-24-011076.Report this figure46.4Total liabilities, Q3 FY2024, at 2024-09-30$46.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure36.3Total liabilities, FY2024, at 2024-12-31$36.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-12, accession 0001104659-26-027047.Report this figure10.1Total liabilities, Q1 FY2025, at 2025-03-31$10.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure9.2Total liabilities, Q2 FY2025, at 2025-06-30$9.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure8.7Total liabilities, Q3 FY2025, at 2025-09-30$8.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure9.9Total liabilities, FY2025, at 2025-12-31$9.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure12.5Total liabilities, Q1 FY2026, at 2026-03-31$12.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure13.9Total liabilities, Q2 FY2026, at 2026-06-30$13.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure
Shareholders' equity$m44.3Shareholders' equity, Q3 FY2023, at 2023-09-30$44.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure38.7Shareholders' equity, FY2023, at 2023-12-31$38.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-12, accession 0001104659-26-027047.Report this figure33.4Shareholders' equity, Q1 FY2024, at 2024-03-31$33.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure51.2Shareholders' equity, Q2 FY2024, at 2024-06-30$51.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure12.4Shareholders' equity, Q3 FY2024, at 2024-09-30$12.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure32.6Shareholders' equity, FY2024, at 2024-12-31$32.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure49.3Shareholders' equity, Q1 FY2025, at 2025-03-31$49.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure80.2Shareholders' equity, Q2 FY2025, at 2025-06-30$80.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure71.8Shareholders' equity, Q3 FY2025, at 2025-09-30$71.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure61.2Shareholders' equity, FY2025, at 2025-12-31$61.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure241Shareholders' equity, Q1 FY2026, at 2026-03-31$240.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure225Shareholders' equity, Q2 FY2026, at 2026-06-30$225.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure

Cash flow

Operating cash flow−$15.4m, Q2 FY2026
Capital expenditure$582.0k, Q2 FY2026
Corvus Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(5.4)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001558370-24-015306. Derived: 9-month figure less the 6-month figure.Report this figure(5.2)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(5.2)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure(5.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001558370-25-010755. Derived: 6-month figure less the 3-month figure.Report this figure(6.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$6.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001104659-25-106259. Derived: 9-month figure less the 6-month figure.Report this figure(8.5)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$8.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(8.3)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$8.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(5.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091975. Derived: 6-month figure less the 3-month figure.Report this figure(9.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$9.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001104659-25-106259. Derived: 9-month figure less the 6-month figure.Report this figure(9.2)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure(10.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure(15.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$15.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091975. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001558370-24-015306. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$36.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$113.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091975. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001104659-25-106259. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$25.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001104659-26-027047. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$91.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure0.6Capital expenditure, Q2 FY2026, three months to 2026-06-30$582.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091975. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)92.37m, Q2 FY2026
Corvus Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares46.6Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3046,553,511 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0001558370-23-017981.Report this figure46.6Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3146,556,178 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001558370-24-007093.Report this figure47.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3047,497,414 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001558370-24-011076.Report this figure49.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3048,971,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001558370-24-015306.Report this figure49.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3149,038,582 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001558370-25-006966.Report this figure59.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3059,710,265 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001558370-25-010755.Report this figure66.7Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3066,701,086 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure75.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3175,152,514 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure77.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3077,774,344 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure82.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3082,836,369 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001104659-25-106259.Report this figure90.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3189,996,728 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-057100.Report this figure92.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3092,368,013 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure

Shares outstanding: 84.12mShares outstanding, period not labelled, at 2026-08-0684,120,944 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091975.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.